High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisions
Open Access
- 22 August 2014
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 99 (12) , e257-e259
Abstract
Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. EKeywords
This publication has 14 references indexed in Scilit:
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemiaNature Medicine, 2010
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcomeBlood, 2009
- Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9Nature, 2006
- ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with β-catenin defects and promotes neoplastic transformationCancer Cell, 2002
- A Splice Variant of the ITF-2 Transcript Encodes a Transcription Factor That Inhibits MyoD ActivityJournal of Biological Chemistry, 1996
- Crystal structure of transcription factor E47: E-box recognition by a basic region helix-loop-helix dimer.Genes & Development, 1994
- Two Distinct Transcription Factors that Bind the Immunoglobulin Enhancer μE5/κE2 MotifScience, 1990